Scientists on Thursday announced a major advance in the war on malaria, reporting promising results from a test vaccine which could slash the toll of death, sickness and poverty inflicted by this disease.
In an intermediate trial among Mozambican children, the vaccine reduced the risk of falling sick from malaria by nearly 30 percent and more than halved the risk of contracting severe malaria, which is potentially fatal.
Researchers, pharmaceutical executives and campaigners behind the prototype stressed it is not the Holy Grail of a totally effective vaccine against malaria.
And they cautioned that -- if all goes well in further trials -- the product is unlikely to be available before 2010 at the earliest.
Even so, they were jubilant.
They described the results as the first clear success in a decades-long quest for a vaccine, and one that could dramatically help sub-Saharan Africa, home to 90 percent of the world's malaria victims.
"Today we are facing an important milestone in humankind's battle against malaria," Jean Stephenne, president of GSK Biologicals, a unit of the pharmaceuticals giant GlaxoSmithKline (GSK), which engineered the vaccine, said in a teleconference with journalists.
"This is a scientific breakthrough," declared Melinda Moree, director of the Malaria Vaccine Initiative (MVI), a program backed by the Bill and Melinda Gates Foundation to bring private- and public-sector resources together against malaria.
"These results are far better than anything that has been seen before," she said. "This is a vaccine that could have a significant impact on public health."
Malaria is caused by a tiny parasite that is passed on when a female mosquito of the Anopheles gambiae strain draws human blood for a meal.
The parasite, still in its early stage of development, heads to the liver, where it grows and then swarms out, infecting red blood cells and destroying them. The consequences are fever and anaemia and, in severe cases where blood supply to the brain is affected, cerebral malaria.
Between one million and three million people die from malaria each year, and up to 300 million people a year fall sick from it, according to various estimates.
The trial vaccine, RTS,S/AS02A, has been in the making for more than 15 years.
It comprises proteins taken from the Plasmodium falciparum parasite in its early stage, a form known as a sporozoite. These proteins are fused into a tried-and-tested hepatitis B vaccine.
Phase I trials, conducted among a small number of human volunteers in the US and Africa, showed the vaccine was safe and primed antibodies and immune cells to recognize P. falciparum as an intruder.
Larger trials, called Phase IIb, were then carried out among 2,022 children aged between one and four in Manhica, in the southern Mozambican province of Maputo, where there is a year-round malaria risk.
The infants were randomly divided into two groups. One received three doses of the candidate malaria vaccine, and the other group was given three doses of another vaccine, designed for hepatitis B or the pneumonococcal or haemophilus influenza bacteria.
A follow-up examination six months later showed the risk of developing malaria symptoms was down by 29.9 percent in the first group as compared to the second.
Among those who did fall sick, the risk of becoming severely ill was down 57.9 percent in the first group.
The study is published in this Saturday's issue of The Lancet, the British medical weekly.
Wider tests, called Phase III trials, must now be carried to ensure that the vaccine is truly safe and effective.
Vaccines are one of the most neglected areas of pharmaceutical research. Big drug corporations prefer to look for treatments and cures as these are far more profitable than prevention, especially for diseases that affect poverty-stricken countries.
That is why the latest approach in vaccines for malaria and also for the AIDS virus are public-private partnerships. Charities and philanthropists promise a reasonable profit provided Big Pharma devises, tests and manufactures a good vaccine candidate.
SEEKING CHANGE: A hospital worker said she did not vote in previous elections, but ‘now I can see that maybe my vote can change the system and the country’ Voting closed yesterday across the Solomon Islands in the south Pacific nation’s first general election since the government switched diplomatic allegiance from Taiwan to Beijing and struck a secret security pact that has raised fears of the Chinese navy gaining a foothold in the region. The Solomon Islands’ closer relationship with China and a troubled domestic economy weighed on voters’ minds as they cast their ballots. As many as 420,000 registered voters had their say across 50 national seats. For the first time, the national vote also coincided with elections for eight of the 10 local governments. Esther Maeluma cast her vote in the
Nearly half of China’s major cities are suffering “moderate to severe” levels of subsidence, putting millions of people at risk of flooding, especially as sea levels rise, according to a study of nationwide satellite data released yesterday. The authors of the paper, published by the journal Science, found that 45 percent of China’s urban land was sinking faster than 3mm per year, with 16 percent at more than 10mm per year, driven not only by declining water tables, but also the sheer weight of the built environment. With China’s urban population already in excess of 900 million people, “even a small portion
UNSETTLING IMAGES: The scene took place in front of TV crews covering the Trump trial, with a CNN anchor calling it an ‘emotional and unbelievably disturbing moment’ A man who doused himself in an accelerant and set himself on fire outside the courthouse where former US president Donald Trump is on trial has died, police said yesterday. The New York City Police Department (NYPD) said the man was declared dead by staff at an area hospital. The man was in Collect Pond Park at about 1:30pm on Friday when he took out pamphlets espousing conspiracy theories, tossed them around, then doused himself in an accelerant and set himself on fire, officials and witnesses said. A large number of police officers were nearby when it happened. Some officers and bystanders rushed
HYPOCRISY? The Chinese Ministry of Foreign Affairs yesterday asked whether Biden was talking about China or the US when he used the word ‘xenophobic’ US President Joe Biden on Wednesday called for a hike in steel tariffs on China, accusing Beijing of cheating as he spoke at a campaign event in Pennsylvania. Biden accused China of xenophobia, too, in a speech to union members in Pittsburgh. “They’re not competing, they’re cheating. They’re cheating and we’ve seen the damage here in America,” Biden said. Chinese steel companies “don’t need to worry about making a profit because the Chinese government is subsidizing them so heavily,” he said. Biden said he had called for the US Trade Representative to triple the tariff rates for Chinese steel and aluminum if Beijing was